908 Devices (NASDAQ:MASS) Earns “Sell (D-)” Rating from Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of 908 Devices (NASDAQ:MASS) in a report published on Tuesday,Weiss Ratings reports.

Separately, Stephens reaffirmed an “overweight” rating and issued a $6.00 price objective on shares of 908 Devices in a research note on Wednesday, January 15th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.33.

908 Devices Stock Performance

Shares of MASS opened at $3.79 on Tuesday. The firm has a market cap of $133.90 million, a PE ratio of -2.14 and a beta of 0.30. The firm’s 50 day moving average price is $3.34 and its 200 day moving average price is $2.97. 908 Devices has a twelve month low of $1.81 and a twelve month high of $7.48.

Institutional Trading of 908 Devices

A number of institutional investors and hedge funds have recently modified their holdings of MASS. Charles Schwab Investment Management Inc. raised its holdings in 908 Devices by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 220,477 shares of the company’s stock worth $765,000 after acquiring an additional 28,015 shares during the period. Geode Capital Management LLC increased its stake in shares of 908 Devices by 1.2% in the third quarter. Geode Capital Management LLC now owns 567,788 shares of the company’s stock worth $1,970,000 after purchasing an additional 6,634 shares during the period. State Street Corp boosted its stake in 908 Devices by 1.2% during the 3rd quarter. State Street Corp now owns 479,044 shares of the company’s stock valued at $1,662,000 after purchasing an additional 5,704 shares during the period. Barclays PLC grew its holdings in 908 Devices by 452.7% in the 3rd quarter. Barclays PLC now owns 46,214 shares of the company’s stock valued at $160,000 after buying an additional 37,853 shares during the last quarter. Finally, Concurrent Investment Advisors LLC bought a new position in 908 Devices in the 4th quarter worth approximately $52,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.